Treatment Clinical Trials for Chronic Lymphocytic Leukemia

Clinical trials are research studies that involve people. The clinical trials on this list are for chronic lymphocytic leukemia treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 151
1 2 3 ... 7 Next >

  • Ibrutinib and Obinutuzumab with or without Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia

    This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab, and venetoclax may work better than giving ibrutinib and obinutuzumab in treating patients with chronic lymphocytic leukemia.
    Location: 850 locations

  • Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients with Chronic Lymphocytic Leukemia

    This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment. The addition of venetoclax to the usual treatment might prevent chronic lymphocytic leukemia from returning. This trial also will investigate whether patients who receive ibrutinib plus obinutuzumab plus venetoclax and have no detectable chronic lymphocytic leukemia after 1 year of treatment, can stop taking ibrutinib. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and obinutuzumab with venetoclax may work better at treating chronic lymphocytic leukemia compared to ibrutinib and obinutuzumab.
    Location: 763 locations

  • Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    This is a Phase 1 / 2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.
    Location: 25 locations

  • Ibrutinib with or without Cirmtuzumab in Treating Patients with B-Cell Lymphoid Malignancies

    This phase Ib / II trial studies the side effects and best dose of cirmtuzumab when given together with ibrutinib and to see how well they work in treating patients with B-cell lymphoid malignancies. Immunotherapy with cirmtuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving ibrutinib with or without cirmtuzumab may work better in treating patients with B-cell lymphoid malignancies.
    Location: 16 locations

  • Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.

    This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies Part 1 of the study is monotherapy dose escalation. Part 2 of the study is monotherapy expansion groups for relapsed / refractory chronic lymphocytic leukaemia (CLL), AML / myelodysplastic syndromes (MDS), and multiple myeloma (MM) Part 3 is a sequential, dose-escalation study of the combination of AZD5991 and venetoclax in subjects with relapsed / refractory AML / MDS
    Location: 12 locations

  • A Study of Oral LOXO-305 in Patients With Previously Treated CLL / SLL or NHL

    This is an open-label, multi-center Phase 1 / 2 study of oral LOXO-305 in patients with CLL / SLL and NHL who have failed or are intolerant to standard of care.
    Location: 18 locations

  • Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed / Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed / refractory chronic lymphocytic leukemia (r / r CLL) and small lymphocytic lymphoma (r / r SLL).
    Location: 16 locations

  • A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    This is a Phase 1 / 1b dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
    Location: 10 locations

  • Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL

    ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)
    Location: 11 locations

  • A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

    A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
    Location: 9 locations

  • Zanubrutinib, Obinutuzumab, and Venetoclax in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Mantle Cell Lymphoma

    This phase II trial studies how well zanubrutinib, obinutuzumab, and venetoclax work in treating patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma and mantle cell lymphoma. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving zanubrutinib, obinutuzumab, and venetoclax together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma compared to standard therapy, including antibody therapy (a treatment that targets cancer cells) plus chemotherapy.
    Location: 8 locations

  • A Phase 1 / 2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors

    This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1 / 2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed / refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.
    Location: 8 locations

  • A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies

    This is a multi-center, open-label trial to evaluate oral administration of CA-4948 in adult patients with relapsed / refractory hematologic malignancies. Part A will evaluate escalating doses of CA-4948 either as monotherapy (Part A1) or in combination with ibrutinib for non- Hodgkin's Lymphoma (NHL), macroglobulinemia / lymphoplasmacytic lymphoma (WM / LPL) and chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) (Part A2). Once the combination dose has been determined, Part B will comprise an expansion phase to assess efficacy (CR rate) and safety of the RP2D of CA-4948 and ibrutinib in 4 Non-Hodgkin Lymphoma (NHL) disease-specific cohorts: - Cohort 1 - Marginal zone lymphoma (MZL) - Cohort 2 - activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) or extranodal subtypes: Leg-, testicular-, or not otherwise specified (NOS)-type - Cohort 3 - Primary central nervous system lymphoma (PCNSL) - Cohort 4 - Patients receiving ibrutinib monotherapy who have developed adaptive, secondary resistance. Indications include: - Mantle Cell Lymphoma (MCL), MZL, CLL / SLL, or WM / LPL - Indications for which ibrutinib is National Comprehensive Cancer Network (NCCN)-listed (e.g., PCNSL) - Patients with NHL and known myddosome mutations - Patients may be candidates for maintaining ibrutinib while CA-4948 will be added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks is acceptable.
    Location: 10 locations

  • Assessing Minimal Residual Disease to Minimize Exposure in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Who Have Been Treated with Venetoclax, Veneto-STOP Study

    This phase II trial assesses minimal residual disease to minimize exposure in patients with chronic lymphocytic leukemia or small lymphocytic leukemia who have been treated with venetoclax. Stopping treatment with venetoclax in MRD-negative chronic lymphocytic leukemia or small lymphocytic leukemia patients could help prevent the serious side effects that can occur during long-term treatment with this drug. This trial may help researchers find out whether patients who are currently receiving treatment with venetoclax can stop treatment and remain off-treatment for at least 12 months, if they are free of residual disease (MRD-negative) when they stop treatment.
    Location: 10 locations

  • Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

    The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
    Location: 7 locations

  • FORRDuvelisib and Venetoclax in Treating Patients with Richter's Syndrome or Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase I / II trial studies the side effects and best dose of venetoclax when given together with duvelisib and to see how well they work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or does not respond to treatment, or Richter's syndrome. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax targets a protein called BCL-2, which helps cancer cells survive. Combining duvelisib and venetoclax may be able to prevent tumor from growing.
    Location: 7 locations

  • A Study of CG-806 in Patients With Relapsed or Refractory CLL / SLL or Non-Hodgkin's Lymphomas

    This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
    Location: 8 locations

  • A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed / Refractory Chronic Lymphocytic Leukemia

    This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed / refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 7 locations

  • A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

    The primary objective of this study is to compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL / SLL, as measured by progression free survival.
    Location: 7 locations

  • Acalabrutinib, Venetoclax, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well acalabrutinib, venetoclax, and obinutuzumab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib, venetoclax, and obinutuzumab may work better in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 6 locations

  • A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML

    This is a Phase 1, open-label, 3 + 3 dose escalation study to determine the safety and preliminary efficacy of voruciclib in subjects with relapsed / refractory B cell malignancies and AML after treatment with standard therapy.
    Location: 8 locations

  • A Study of ARQ 531 in Patients With Selected Hematologic Malignancies

    This is an open-label, multi-center Phase 1 / 2 study of ARQ 531 in patients with selected hematologic malignancies.
    Location: 6 locations

  • A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies

    This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of VLS-101, an antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) on cancer cells. The study is evaluating VLS-101 in patients with previously treated hematological cancers.
    Location: 6 locations

  • Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)

    This study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy.
    Location: 5 locations

  • Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

    The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and / or recommended dose (RD).
    Location: 5 locations


1 2 3 ... 7 Next >